72nd American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo

Latest clinical data on Bayer mid-stage candidate Vilaprisan to be presented at ASRM

ASTEROID 1-Phase IIb-study results of vilaprisan in patients with symptomatic uterine fibroids

Berlin, October 13, 2016 – Latest clinical data on Bayer’s investigational novel, oral, selective progesterone receptor modulator vilaprisan (BAY 1002670) will be presented at the 72nd American Society of Reproductive Medicine (ASRM) Scientific Congress, which takes place from October 15-19, 2016 in Salt Lake City, UT, USA. The data presented are the results of the Phase IIb study (ASTEROID 1) investigating the efficacy and safety of four different doses of vilaprisan compared to placebo in patients with symptomatic uterine fibroids over a period of twelve weeks.

Presentation on Bayer development candidate vilaprisan at ASRM Scientific Congress 2016:

Results of the ASTEROID (Assess Safety and Efficacy of Vilaprisan in Patients with Uterine Fibroids) 1 study: A Phase 2, Placebo-controlled dose finding study – presented by Linda Bradley (Cleveland, OH, USA)

- Oral Abstract Session: Fibroids, Abstract#: O-235
- Wednesday, October 19, 2016: 11:15 AM to 11:30 AM – Room 355D, Salt Palace Convention Center

Further details can be found at the ASRM website (http://www.asrmcongress.org).
**About Vilaprisan**

Vilaprisan (BAY 1002670) is an investigational novel oral, highly potent and selective progesterone receptor modulator, which is currently in clinical development for the treatment of symptomatic uterine fibroids as well as endometriosis. Modulation of the progesterone receptor (PR) balances out the cycle-dependent, naturally occurring hormonal fluctuations at the PR and inhibits activation of the receptor via progesterone. As a result, menstrual bleeding is discontinued leading to therapeutic amenorrhea (non-bleeding), a condition which can be reversed with treatment cessation. Progesterone receptor modulation may allow long-term treatment of uterine fibroids and endometriosis without the side effects associated with current standard of care.

**About Uterine Fibroids**

Fibroids are the most common benign tumors of the uterus: 5-10% of premenopausal women are suffering from symptomatic fibroids, about 14 million patients alone in the US, Europe and Brazil. Common symptoms include heavy menstrual bleeding, pelvic pressure and pain, as well as bladder, gastrointestinal and reproductive dysfunction. Current therapies include surgical procedures or short-term use of GnRH analogs for therapeutic estrogen depletion, as the growth of fibroids strongly depends on progesterone and estrogen. Recently, the selective progesterone receptor modulator ulipristal acetate was approved for intermittent treatment of uterine fibroids in the EU.

**About Gynecology at Bayer**

Bayer is committed to delivering *Science For A Better Life* by advancing a portfolio of innovative treatments. Women’s health including family planning and menopause management has been in the center of Bayer’s gynecology franchise for many years. Today, our research efforts focus on finding new treatment options for gynecological diseases with a high medical need such as uterine fibroids and endometriosis, which affect a large number of women in our society. The gynecology franchise at Bayer includes several investigational compounds in various stages of preclinical and clinical development. Together, these projects reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that gynecological diseases are treated.
Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.

Our online press service is just a click away: press.bayer.com
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: https://twitter.com/BayerPharma

Contact:
Dr. Julia Schulze, Tel. +49 30 468-193636
E-Mail: julia.schulze@bayer.com

Find more information at www.pharma.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.